These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 38017299)
1. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML. Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299 [TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia. Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768 [TBL] [Abstract][Full Text] [Related]
3. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Al-Harbi S; Aljurf M; Mohty M; Almohareb F; Ahmed SOA Blood Adv; 2020 Jan; 4(1):229-238. PubMed ID: 31935293 [TBL] [Abstract][Full Text] [Related]
4. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164 [TBL] [Abstract][Full Text] [Related]
5. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. Neldeborg S; Soerensen JF; Møller CT; Bill M; Gao Z; Bak RO; Holm K; Sorensen B; Nyegaard M; Luo Y; Hokland P; Stougaard M; Ludvigsen M; Holm CK Leukemia; 2023 Sep; 37(9):1792-1801. PubMed ID: 37464068 [TBL] [Abstract][Full Text] [Related]
6. [Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations]. Han SY; Zhou HX; Han Y; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):767-771. PubMed ID: 39307724 [No Abstract] [Full Text] [Related]
7. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. Redondo Monte E; Wilding A; Leubolt G; Kerbs P; Bagnoli JW; Hartmann L; Hiddemann W; Chen-Wichmann L; Krebs S; Blum H; Cusan M; Vick B; Jeremias I; Enard W; Theurich S; Wichmann C; Greif PA Oncogene; 2020 Apr; 39(15):3195-3205. PubMed ID: 32115572 [TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine deregulates Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143 [TBL] [Abstract][Full Text] [Related]
9. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia. Macke EL; Meyer RG; Hoppman NL; Ketterling RP; Greipp PT; Xu X; Baughn LB; Shafer DA; He RR; Peterson JF Lab Med; 2022 Jul; 53(4):e87-e90. PubMed ID: 34791328 [TBL] [Abstract][Full Text] [Related]
10. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. Tan M; Zhang Q; Yuan X; Chen Y; Wu Y J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525 [TBL] [Abstract][Full Text] [Related]
11. Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report. Asou C; Sakamoto T; Suzuki K; Okuda I; Osaki A; Abe R; Ito Y; Kakegawa E; Miyakawa Y; Terui Y; Nakamura Y J Med Case Rep; 2024 Aug; 18(1):372. PubMed ID: 39154170 [TBL] [Abstract][Full Text] [Related]
12. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540 [TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1. Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410 [TBL] [Abstract][Full Text] [Related]
15. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825 [TBL] [Abstract][Full Text] [Related]
16. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21). Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741 [TBL] [Abstract][Full Text] [Related]
17. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925 [TBL] [Abstract][Full Text] [Related]
18. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy]. Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890 [No Abstract] [Full Text] [Related]
19. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799 [TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]